for up to $3.5-billion to boost its late-stage drug development lineup with a new treatment for a rare severe kidney disease.
Shareholders would also receive a contingent value right worth up to $300-million, depending on certain regulatory achievements, Novartis said. The other drug hopeful is iptacopan, which is being trialled against a rare genetic blood disorder, possibly challenging AstraZeneca’s drugs Soliris and Ultomiris.
It is also working on zigakibart, another experimental IgAN treatment that is injected, and plans to start a late-stage trial in the third quarter.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: